EY | 1 CPE | State of pharma market access in the US

EY | 1 CPE | State of pharma market access in the US

With passage of the Inflation Reduction Act (IRA) in the rearview mirror, policymakers are continuing their charge to address drug prices and the pharmaceutical supply chain, uprooting the status quo of market access in the US and beyond.

Join our webcast to gain new insights from Ernst & Young LLP (EY US) policy and strategy professionals about the market implications for life sciences companies around the evolving policy landscape.

Learn more about:

  • Next steps and analysis following announcement of the first 10 drugs selected for the IRA’s drug negotiation program
  • Leading transparency legislation and regulatory action to shine a light on the pharmaceutical supply chain and M&A
  • Evolving policy in access and coverage, from upcoming Medicaid payment changes to Medicare coverage and payment for innovative drugs
  • Life sciences industry implications and potential disruption for manufacturers, wholesalers, pharmacy benefit managers, payers, patients and beyond

Leave a Comment